Sugi Predict

Sugi Predict / Compounds / SCHEMBL501336

SCHEMBL501336

SCHEMBL501336

CS(=O)(=O)OCc1ccnc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 1/20 0.49
▸ KCNQ2 O43526 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ ADRA1D P25100 1/20 0.42
▸ ADRA1A P35348 1/20 0.42
▸ ADRA1B P35368 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ CCNT1 O60563 4/20 0.39
▸ CDK9 P50750 4/20 0.39
▸ CDK2 P24941 3/20 0.39
▸ CCNE1 P24864 2/20 0.39
▸ KCNH3 Q9ULD8 5/20 0.35
▸ TLR7 Q9NYK1 1/20 0.33
▸ CA2 P00918 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ CCNK O75909 2/20 0.32
▸ CDK1 P06493 1/20 0.32
▸ AKT1 P31749 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29962624 1.00 LOXL2 (0.49) LOXL2KCNQ2CYP3A4ALOX15TSHR
SCHEMBL1210262 0.84 LOXL2 (0.46) LOXL2KCNQ2CYP3A4ALOX15TSHR
SCHEMBL1208002 0.81 LOXL2 (0.44) LOXL2KCNQ2CYP3A4ALOX15TSHR
SCHEMBL615622 0.81 KCNQ2 (0.43) LOXL2KCNQ2CYP3A4TLR7CA2
SCHEMBL1670067 0.80 PARP1 (0.35) LOXL2CYP3A4CDK2CA2CA9
SCHEMBL3116042 0.80 CYP1A2 (0.39) LOXL2CYP3A4TLR7CA2CA9
SCHEMBL5793683 0.80 RECQL (0.49) LOXL2CYP3A4CDK2CA2CA9
SCHEMBL22264304 0.80 LOXL2 (0.53) LOXL2KCNQ2CDK2CA2
SCHEMBL29995228 0.80 LOXL2 (0.53) LOXL2KCNQ2CDK2CA2
SCHEMBL10204294 0.79 CYP1A2 (0.34) CYP3A4ALOX15TSHRTLR7CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171434-A1 SEC61 INHIBITORS AND USE THEREOF ENODIA THERAPEUTICS SAS (FR) 2025-05-29 — — US disclosed
EP-4486451-A1 SEC61 INHIBITORS AND USE THEREOF Kezar Life Sciences, Inc. (US) 2025-01-08 — — EP disclosed
EP-4402139-A1 FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS Bisichem Co., Ltd. (KR) 2024-07-24 — — EP disclosed
US-20240083892-A1 FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS BISICHEM CO., LTD. (KR) 2024-03-14 — — US disclosed
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-02-15 — — US disclosed
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-09-14 — — US disclosed
WO-2023164250-A1 SEC61 INHIBITORS AND USE THEREOF KEZAR LIFE SCIENCES (US) 2023-08-31 — — WO disclosed
WO-2023164250-A1 SEC61 INHIBITORS AND USE THEREOF KEZAR LIFE SCIENCES (US) 2023-08-31 — — WO disclosed
US-11725001-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-08-15 — — US disclosed
WO-2023043284-A1 FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS BISICHEM CO., LTD. (KR) 2023-03-23 — — WO disclosed
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2010-02-11 — — US disclosed
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2010-02-11 — — US disclosed
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2010-02-11 — — US disclosed
WO-2009095872-A2 LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2009-08-06 — — WO disclosed
WO-2009095872-A2 LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2009-08-06 — — WO disclosed
CN-101495461-A Novel HIV reverse transcriptase inhibitors GILEAD SCIENCES INC (US) 2009-07-29 — — CN disclosed
EP-2044037-A2 HIV REVERSE TRANSCRIPTASE INHIBITORS Gilead Sciences, Inc. (US) 2009-04-08 — — EP disclosed
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-03-20 — — US disclosed
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-03-20 — — US disclosed
WO-2008016522-A2 HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083892-A1 FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS RIPK1, RIPK3, RIPK4 LOXL2 2980/4885KCNQ2 4282/4885CYP3A4 2475/4885
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS POLR2E, POLRMT, POLR2H LOXL2 4462/4885KCNQ2 4209/4885CYP3A4 1326/4885
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 LOXL2 3165/4885KCNQ2 4125/4885CYP3A4 3664/4885
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT8 LOXL2 3017/4885KCNQ2 4309/4885CYP3A4 4087/4885
US-11725001-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 LOXL2 3165/4885KCNQ2 4125/4885CYP3A4 3664/4885
US-20250171434-A1 SEC61 INHIBITORS AND USE THEREOF SEC61B, SEC61A1, SEC61G LOXL2 4139/4885KCNQ2 4004/4885CYP3A4 1636/4885
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors POLR2E, POLRMT, POLR2H LOXL2 4467/4885KCNQ2 4224/4885CYP3A4 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.